宫颈癌淋巴结分期中[68Ga]Ga-FAPI-46 PET/CT与[18F]F-FDG PET/CT的首次临床经验对比
本研究纳入7例初治活检证实的局部晚期宫颈癌患者,在系统腹腔镜盆腔及腹主动脉旁淋巴结清扫术前,先后行[68Ga]Ga-FAPI-46与[18F]F-FDG全身PET/CT,并与组织病理(含FAP免疫组化)对照。结果显示FAPI-46在原发灶及淋巴结转移灶的靶本比均更高,检出病灶更多;手术病理确诊5枚转移淋巴结,FDG阳性2枚、FAPI-46阳性4枚。作者认为FAPI-46 PET/CT似乎有助于改善宫颈癌淋巴结转移的检出。
要点
- 7例局部晚期宫颈癌患者中,FAPI-46 PET/CT原发灶及淋巴结转移灶靶本比均高于FDG PET/CT。
- 以肝脏为本底,原发灶中位TBRmax为FAPI-46 32.02、FDG 5.15;血池本底为18.45 vs 6.85。
- 病理确诊5枚转移淋巴结,FDG检出2枚、FAPI-46检出4枚;FAPI-46总体检出病灶更多。
核心结论
- 作者认为[68Ga]Ga-FAPI-46 PET/CT似乎有助于改善宫颈癌患者淋巴结转移的检出。
- 作者提出未来研究应旨在将[68Ga]Ga-FAPI-46 PET/CT与局部晚期宫颈癌患者的盆腔及腹主动脉旁淋巴结手术分期进行比较。
研究设计与样本
- 本研究为首次临床经验研究,连续纳入7例初治、活检证实的局部晚期宫颈癌女性患者。
- 患者在初次放化疗前、系统腹腔镜盆腔及腹主动脉旁淋巴结清扫术前,接受全身[68Ga]Ga-FAPI-46与[18F]F-FDG PET/CT以进行淋巴结分期影像评估。
- 记录PET显像中可疑淋巴结的位置与数量,并与组织病理学分析结果(包括FAP免疫组化染色)进行比较。
主要发现
- 7例患者的肿瘤病灶在[68Ga]Ga-FAPI-46 PET/CT中均表现为高于本底的局灶性摄取。
- 原发灶中位TBRmax(以肝脏为本底)为[68Ga]Ga-FAPI-46 32.02 vs [18F]F-FDG 5.15;以血池为本底为18.45 vs 6.85。
- 淋巴结转移灶中位TBRmax为[68Ga]Ga-FAPI-46 14.55 vs [18F]F-FDG 1.39(肝脏本底),以及7.97 vs 1.8(血池本底)。
- 总体而言,[68Ga]Ga-FAPI-46 PET/CT检出的病灶数多于[18F]F-FDG PET/CT。
- 手术分期后病理确诊共5枚转移淋巴结,其中[18F]F-FDG PET/CT阳性2枚、[68Ga]Ga-FAPI-46 PET/CT阳性4枚。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论提出未来研究应旨在将[68Ga]Ga-FAPI-46 PET/CT与局部晚期宫颈癌患者的盆腔及腹主动脉旁淋巴结手术分期进行比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In several solid tumors, fibroblast activation protein (FAP) is overexpressed by cancer-associated fibroblasts in the tumor microenvironment. Preliminary evidence suggests that detection and staging are feasible with PET/CT imaging using [68Ga]-radiolabeled inhibitors of FAP also in cervical cancer (CC). Our study aims to explore the accuracy of [68Ga]Ga-fibroblast activation protein inhibitor (FAPI)-46 PET/CT and [18F]F-FDG PET/CT compared with histopathological results of surgical lymph node (LN) staging before primary chemoradiation. METHODS: Seven consecutive women with treatment-naive and biopsy-proven locally advanced CC underwent both whole-body [68Ga]Ga-FAPI-46- and [18F]F-FDG PET/CT, for imaging nodal staging before systematic laparoscopic lymphadenectomy of the pelvic and para-aortic region. Location and number of suspicious LNs in PET imaging were recorded and compared with the results of histopathological analysis, including immunohistochemical staining for FAP. RESULTS: All 7 patients had focal uptake above background in their tumor lesions in [68Ga]Ga-FAPI-46 PET/CT. [68Ga]Ga-FAPI-46 PET/CT showed a higher tumor-to-background ratio (TBR) in primary tumor as well as in LN metastasis. Median TBRmax values using liver were 32.02 and 5.15 for [68Ga]Ga-FAPI-46 PET/CT and [18F]F-FDG PET/CT, respectively. Median TBRmax using blood pool was 18.45 versus 6.85 for [68Ga]Ga-FAPI-46 PET/CT and [18F]F-FDG PET/CT, respectively. Higher TBR also applies for nodal metastasis: TBRmax was 14.55 versus 1.39 (liver) and 7.97 versus 1.8 (blood pool) for [68Ga]Ga-FAPI-46 PET/CT and [18F]F-FDG PET/CT, respectively. Overall, [68Ga]Ga-FAPI-46 PET/CT detected more lesions compared with [18F]F-FDG PET/CT. Following surgical staging, a total of 5 metastatic LNs could be pathologically confirmed, of which 2 and 4 were positive by [18F]F-FDG PET/CT and [68Ga]Ga-FAPI-46 PET/CT, respectively. CONCLUSION: [68Ga]Ga-FAPI-46 PET/CT seems useful to improve detection of nodal metastasis in patients with CCs. Future studies should aim to compare [68Ga]Ga-FAPI-46 PET/CT to surgical staging of pelvic and para-aortic LNs in patients with locally advanced CC.
引用
- Wegen S, Roth KS, Weindler J, et al. First Clinical Experience With [68Ga]Ga-FAPI-46-PET/CT Versus [18F]F-FDG PET/CT for Nodal Staging in Cervical Cancer. Clin Nucl Med. 2023. PMID: 36607364. doi:10.1097/RLU.0000000000004505
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。